CWBR News and Press, CohBar Inc. From 11/11/22

CohBar, Inc. (CWBR) Q3 2022 Results Conference Call November 8, 2022 10:00 AM ET Company Participants Jordyn Tarazi - Director of IR Joseph Sarret - CEO Kent Grindstaff - SVP, Research Jeffrey Biunno - CFO Conference Call Participants Kemp Dollive...

CohBar press release ( NASDAQ: CWBR ): Q3 GAAP EPS of -$0.82. The company had cash, cash equivalents and investments of $18.3 million as of September 30, 2022, compared to $26.2 million as of December 31, 2021. For further details see: CohBar GAAP EPS of -$0.82 ...

MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases...

MENLO PARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases...

CohBar ( NASDAQ: CWBR ) shares gained 16% premarket on Thursday after the biotech firm announced a 1-for-30 reverse stock split of its common stock. The move is intended to enable the company to regain compliance with the Nasdaq $1.00 minimum bid price requirement. The...

MENLO PARK, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related disease...

MENLO PARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related disease...

CohBar, Inc. (CWBR) Q2 2022 Earnings Conference Call August 15, 2022, 05:00 PM ET Company Participants Jordyn Tarazi - Director of IR Joe Sarret - CEO Jeff Biunno - CFO Nick Vlahakis - Acting CMO Kent Grindstaff - SVP, Research Conference Call Parti...

CohBar press release ( NASDAQ: CWBR ): Q2 GAAP EPS of -$0.03 beats by $0.01 . The company had cash, cash equivalents and investments of $20.1 million as of June 30 IND for CB5138-3 on track for second half of 2023 For further details see: CohBar GAAP EPS ...

IND for CB5138-3 on track for second half of 2023 Conference call and webcast today at 5:00 p.m. ET, August 15, 2022 MENLO PARK, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitoch...